Cornillon, Jérôme Carre, Martin Chalandon, Yves Chevallier, Patrice Coman, Teresa Harif, Mhamed Labuissière-Wallet, Hélène Mear, Jean-Baptiste Picard, Christophe Yakoub-Agha, Ibrahim
...
Published in
Bulletin du cancer
Microtransplantation (MT) is based on injection of HLA-mismatched G-CSF mobilized hematopoietic stem cells, in combination with chemotherapy but without use of conditioning regimen nor immunosuppressive drugs. As a result, a transient microchimerism is induced without engraftment. Its efficacy relies both on host immune system stimulation (recipien...
Borel, Cécile Ahmad, Imran Ceballos, Patrice Desbrosses, Yohann Hamzy, Fati Ravinet, Aurélie Souchet, Laetitia Turlure, Pascal Villate, Alban Yakoub-Agha, Ibrahim
...
Published in
Bulletin du cancer
Allogeneic stem cell transplantation is currently the only curative therapy for hematological disorders. This treatment can lead to complications, of which ophtalmological involvement. We reviewed the literature and established accessible and convenient recommendations for hematologists and ophthalmologists. Ophtalmological follow-up should be done...
Delbos, Florent Blouin, Laura Bruno, Bénédicte Crocchiolo, Roberto Desoutter, Judith Detrait, Marie Nguyen-Lejarre, Khan Tien Giannoli, Catherine Lemarié, Claude Renac, Virginie
...
Published in
Bulletin du cancer
The presence of allo-antibodies in the serum of a recipient awaiting hematopoietic stem cell transplantation (HSCT) may have an impact on transfusion efficiency and/or donor choice, especially in the absence of an identical sibling donor. Prior to transplantation, donor specific anti-HLA (Human Leukocyte Antigen) antibodies (DSA) have a recognized ...
Vasseur, Alyette Karam, Micheline Chaillou, Delphine Colonnese, Elodie Dantin, Carole Latiere, Christelle Meziane, Youcef Pereira, Maguy Yakoub-Agha, Ibrahim Chabannon, Christian
...
Published in
Bulletin du cancer
Tisagenlecleucel (Kymriah™) and axicabtagene ciloleucel (Yescarta™) are the first two approved drug products that belong to of a new class of therapies manufactured through an industrial process that includes the ex vivo genetic modification of human autologous T lymphocytes with viral vectors. Since CAR-T Cells qualify as gene therapy medicinal pr...
Souchet, Laetitia Ahmad, Imran Hamzy, Fati Ceballos, Patrice Desbrosses, Yohann Ravinet, Aurélie Turlure, Pascal Villate, Alban Vigarios, Emmanuelle Borel, Cécile
...
Published in
Bulletin du cancer
Stomatological complications of allogeneic hematopoietic stem cell transplantation (HSCT) are frequent and very uncomfortable for patients. The primary complication is the graft versus host disease reaction. Other side effects of the procedure include infections, taste disorders and carcinogenic risks. Various local treatments are used but remain i...
Thebaud, Estelle Bertozzi, Anne Isabelle Bauvin, Eric Empereur, Fabienne
Published in
Bulletin du cancer
Regional cancer networks missions have been defined by successive "Plan Cancer" and are focused on coordination and the safety and quality of care. Regional pediatric oncology networks, considering the specific care pathways, have these same coordination missions. The examples of partnership of the oncoped-PL (Pays de Loire) and oncomip (Occitanie)...
Boilève, Alice Samalin, Emmanuelle
Published in
Bulletin du cancer
Cavadias, Iphigénie Rouzier, Roman Lerebours, Florence Héquet, Delphine
Published in
Bulletin du cancer
Breast cancer is the most frequently diagnosed cancer in women and the first cause of cancer death in France. Among the different subtypes of breast cancer, the predominant form is characterized by positive hormone receptors (more than 70% of breast cancers). Hormone therapy thus plays a key role in the strategy of management of these cancers both ...
Delaye, Matthieu Rodrigues, Manuel
Published in
Bulletin du cancer
Alexandre, Jérôme Le Frere-Belda, Marie Aude Prulhiere, Karine Treilleux, Isabelle Leary, Alexandra Pomel, Christophe Chargari, Cyrus Ducassou, Anne Joly, Florence
Published in
Bulletin du cancer
Endometrial cancer is a common cancer in older women and is often associated with comorbidities. Management of metastatic disease and/or relapse requires a multidisciplinary approach. Recent advances in the understanding of oncogenesis and molecular classification of endometrial cancers offer new therapeutic perspectives. These first recommendation...
